# A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

> **NCT04866134** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Erasca, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** ERAS-007
- **DRUG:** ERAS-601

## Key facts

- **NCT ID:** NCT04866134
- **Lead sponsor:** Erasca, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-07
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-11-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04866134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04866134, "A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04866134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*